- Home
- ANAB vs EOSE Comparison
ANAB vs EOSE Comparison
Compare ANAB & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | EOSE |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANAB | EOSE |
|---|---|---|
| Price | $47.64 | $1.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $87.25 | $6.19 |
| AVG Volume (30 Days) | 447.0K | ★ 23.8M |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $114,203,000.00 |
| Revenue This Year | N/A | $168.84 |
| Revenue Next Year | $69.42 | $87.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 157.01 | ★ 631.79 |
| 52 Week Low | $30.27 | $1.59 |
| 52 Week High | $73.30 | $19.86 |
Technical Indicators
Market Signals| Indicator | ANAB | EOSE |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 37.85 |
| Support Level | $44.38 | N/A |
| Resistance Level | $51.94 | $4.45 |
| Average True Range (ATR) | 2.27 | 0.20 |
| MACD | 0.25 | 0.06 |
| Stochastic Oscillator | 44.55 | 50.86 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector.